Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today that it has earned its ISO 9001:2015 certification. The ...
With the business potentially at an important milestone, we thought we'd take a closer look at Codexis, Inc.'s (NASDAQ:CDXS) future prospects. Codexis, Inc. provides enzymatic solutions for ...
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...
Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per ...
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading enzyme engineering company, today announced the launch of a new mini documentary as part of an ongoing campaign ...
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointments ...
REDWOOD CITY, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a ...
REDWOOD CITY, Calif. and BEVERLY, Mass.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the ...
The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March. On one hand, management expects full-year 2019 revenue to grow about 16% year-over-year. On ...
Despite nearly meeting its full-year 2019 product revenue guidance after just three quarters, the company didn't raise guidance. What does that mean? One sign of the business model's lumpiness is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results